Buscar

Estamos realizando la búsqueda. Por favor, espere...

Detalle_Publicacion

Bacteremia in Systemic Lupus Erythematosus in Patients From a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes

Abstract: Objective: To describe the incidence of bacteremia in a large multicentric cohort of patients with systemic lupus erythematosus (SLE) and their clinical characteristics and to identify risk factors. Methods: All bacteremic episodes from the Spanish RELESSER registry were included. Clinical and laboratory characteristics concerning bacteremia and SLE status, as well as comorbidities at the time of infection, were retrospectively collected. A comparison with sex- and age-matched SLE controls without bacteremia was made. A logistic regression was conducted. Results: The study included 114 episodes of bacteremia in 83 patients. The incidence rate was 2.7/1000 patient-years. At the time of bacteremia, the median age was 40.5 (range: 8-90) years, and 88.6% of patients were female. The Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index was 4 [interquartile range (IQR) 8]; 41% had an SLE flare (66% severe); Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index was 3 (IQR 4). A comorbidity was recorded in 64% of cases. At the time of bacteremia, 88.6% received corticosteroids (68.6% > 10 mg/day) and 57% immunosuppressors. Gram-negative bacilli, most frequently Escherichia coli (29.8%), caused 52.6% of the episodes. The bacteremia-related mortality was 14% and bacteremia was recurrent in 27.2% of cases. A dose-response relationship was found between corticosteroids and bacteremia risk. In the multivariate analysis, these factors were associated with bacteremia: elevated creatinine (OR 1.31, 95% CI 1.01-1.70; p = 0.045), diabetes (OR 6.01, 95% CI 2.26-15.95; p < 0.001), cancer (OR 5.32, 95% CI 2.23-12.70; p < 0.001), immunosuppressors (OR 6.35, 95% CI 3.42-11.77; p < 0.001), and damage (OR 1.65, 95% CI 1.31-2.09; p < 0.001). Conclusion: Bacteremia occurred mostly in patients with active SLE and was frequently associated with severe flares and corticosteroid use. Recurrence and mortality were high. Immunosuppressors, comorbidities, and disease-related damage were associated with bacteremia.

Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria

 Fuente: J Rheumatol. 2020 47 (2), 234-240

Editorial: The Journal of Rheumatology Publishing Company Limited

 Año de publicación: 2020

Nº de páginas: 29

Tipo de publicación: Artículo de Revista

 DOI: 10.3899/jrheum.180882

ISSN: 0315-162X

Url de la publicación: https://www.doi.org/10.3899/jrheum.180882

Autoría

RÚA-FIGUEROA, IÑIGO

LÓPEZ-LONGO, FRANCISCO J.

CAMPO, VÍCTOR DEL

GALINDO-IZQUIERDO, MARÍA

URIARTE, ESTHER

TORRE-CISNEROS, JULIÁN

VELA, PALOMA

TOMERO, EVA

NARVÁEZ, JAVIER

OLIVÉ, ALEJANDRO

FREIRE, MERCEDES

SALGADO, EVA

ANDREU, JOSÉ LUIS

CALVO ALÉN, JAIME

HERNÁNDEZ CRUZ, BLANCA

RAYA, ENRIQUE

QUEVEDO, VÍCTOR

EXPÓSITO PÉREZ, LORENA

FERNÁNDEZ NEBRO, ANTONIO